Akebia Reports Q4 Earnings Beat with Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy AKBA?
Source: seekingalpha
- Earnings Performance: Akebia's Q4 GAAP EPS of -$0.05 missed expectations by $0.01, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported Q4 revenue of $57.6 million, a 23.9% year-over-year increase, surpassing market expectations by $11.51 million, suggesting sustained demand for its products and laying a foundation for future performance.
- Market Reaction: Although the EPS fell short of expectations, the strong revenue growth may boost investor confidence and drive stock price recovery, reflecting a positive sentiment towards Akebia's future prospects.
- Industry Outlook: Akebia presented its future outlook at the Guggenheim Securities Biotech Summit, highlighting upcoming catalysts that could attract more investor interest in its long-term potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKBA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKBA
Wall Street analysts forecast AKBA stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.550
Low
4.00
Averages
5.00
High
6.00
Current: 1.550
Low
4.00
Averages
5.00
High
6.00
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Akebia Initiates Phase 1 Trial for AKB-9090 in Cardiac Surgery-Associated AKI
- Trial Launch: Akebia Therapeutics has announced the dosing of the first participants in its Phase 1 clinical trial for AKB-9090, aimed at treating cardiac surgery-associated acute kidney injury, showcasing the company's innovative potential in kidney disease treatment.
- Study Design Details: The trial is a randomized, double-blind, placebo-controlled study designed to enroll up to 70 healthy adult participants to evaluate the safety, tolerability, and pharmacokinetics of AKB-9090, which is expected to provide critical data for future clinical applications.
- Market Demand Opportunity: As a HIF-PH inhibitor targeting acute kidney injury, AKB-9090 addresses a significant unmet medical need, and if successfully developed, it could greatly improve patient outcomes and enhance Akebia's competitiveness in the biopharmaceutical market.
- Future Outlook: Akebia plans to report top-line data in early 2027 to further validate the clinical efficacy of AKB-9090, while also evaluating other kidney disease treatment programs, indicating its ongoing commitment to investment and strategic development in the nephrology field.
See More
Guardian Pharmacy Shares Surge 9.1% Amid Strong Investor Confidence
- Stock Performance: Guardian Pharmacy Services (GRDN) shares surged 9.1% in the last trading session to close at $37.25, reflecting heightened investor confidence in its product portfolio and notable trading volume exceeding typical levels.
- Earnings Expectations: The company is expected to report quarterly earnings of $0.24 per share, representing a year-over-year increase of 14.3%, with revenues projected at $329.68 million, up 0.1% from the previous year, indicating sustained competitiveness in the long-term care pharmacy market.
- Estimate Revision Trend: Over the past 30 days, the consensus EPS estimate for GRDN has been revised 4.8% higher, and such positive revision trends are often correlated with stock price appreciation, suggesting potential future gains.
- Market Position: GRDN currently holds a Zacks Rank of #1 (Strong Buy), further reflecting market recognition of its position and growth potential within the medical drugs industry.
See More
Akebia (AKBA) Q4 2025 Earnings Call Transcript
See More
Akebia Expects Significant Revenue Growth for Vafseo in 2026
- Revenue Growth Outlook: Akebia anticipates significant revenue growth for Vafseo by 2026, driven by expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates, enhancing the company's competitive position in the chronic kidney disease treatment market.
- Clinical Trial Advancements: The company plans to initiate mid-stage trials for AKB-097 targeting rare kidney diseases in the second half of 2026, with initial data expected in 2027, which will provide new growth avenues for its product pipeline.
- Strong Financial Position: As of Q4, Akebia reported cash and cash equivalents of approximately $184.8 million, which is expected to fund its current operating plan for at least two years, providing financial stability for research and market expansion.
- Positive Market Sentiment: On Stocktwits, retail sentiment around AKBA stock shifted from 'neutral' to 'bullish', reflecting investor optimism regarding the accelerating adoption of Vafseo and the company's cash reserves, despite a 28% decline in stock price over the past year.
See More
Akebia Therapeutics Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Akebia reported total net product revenue of $227 million for 2025, with Vafseo and Auryxia as key contributors, indicating strong performance in the kidney disease treatment market and positioning Vafseo as a potential standard of care in a $1 billion market opportunity.
- Clinical Data Support: At the ASN meeting, Akebia presented clinical data showing Vafseo's hospitalization rate was 7.7% lower than the ESA comparator, with a 16% reduction in hospitalization days, which is expected to enhance physician utilization and drive sales growth.
- Pipeline Expansion: The company plans to initiate a Phase II open-label trial for AKB-097 in the second half of 2026, indicating Akebia's strategic expansion into rare kidney diseases, leveraging its expertise in kidney drug development to enhance market competitiveness.
- Improved Financial Position: Total revenues for Q4 2025 were $57.6 million, with net loss reduced to $12.2 million compared to $22.8 million in the same quarter last year, reflecting effective cost control and revenue enhancement measures, while cash and cash equivalents stood at $184.8 million, sufficient to support operations for the next two years.
See More
Akebia Reports Q4 Earnings Beat with Revenue Growth
- Earnings Performance: Akebia's Q4 GAAP EPS of -$0.05 missed expectations by $0.01, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported Q4 revenue of $57.6 million, a 23.9% year-over-year increase, surpassing market expectations by $11.51 million, suggesting sustained demand for its products and laying a foundation for future performance.
- Market Reaction: Although the EPS fell short of expectations, the strong revenue growth may boost investor confidence and drive stock price recovery, reflecting a positive sentiment towards Akebia's future prospects.
- Industry Outlook: Akebia presented its future outlook at the Guggenheim Securities Biotech Summit, highlighting upcoming catalysts that could attract more investor interest in its long-term potential.
See More
Akebia Initiates Phase 1 Trial for AKB-9090 in Cardiac Surgery-Associated AKI
- Trial Launch: Akebia Therapeutics has announced the dosing of the first participants in its Phase 1 clinical trial for AKB-9090, aimed at treating cardiac surgery-associated acute kidney injury, showcasing the company's innovative potential in kidney disease treatment.
- Study Design Details: The trial is a randomized, double-blind, placebo-controlled study designed to enroll up to 70 healthy adult participants to evaluate the safety, tolerability, and pharmacokinetics of AKB-9090, which is expected to provide critical data for future clinical applications.
- Market Demand Opportunity: As a HIF-PH inhibitor targeting acute kidney injury, AKB-9090 addresses a significant unmet medical need, and if successfully developed, it could greatly improve patient outcomes and enhance Akebia's competitiveness in the biopharmaceutical market.
- Future Outlook: Akebia plans to report top-line data in early 2027 to further validate the clinical efficacy of AKB-9090, while also evaluating other kidney disease treatment programs, indicating its ongoing commitment to investment and strategic development in the nephrology field.
See More
Guardian Pharmacy Shares Surge 9.1% Amid Strong Investor Confidence
- Stock Performance: Guardian Pharmacy Services (GRDN) shares surged 9.1% in the last trading session to close at $37.25, reflecting heightened investor confidence in its product portfolio and notable trading volume exceeding typical levels.
- Earnings Expectations: The company is expected to report quarterly earnings of $0.24 per share, representing a year-over-year increase of 14.3%, with revenues projected at $329.68 million, up 0.1% from the previous year, indicating sustained competitiveness in the long-term care pharmacy market.
- Estimate Revision Trend: Over the past 30 days, the consensus EPS estimate for GRDN has been revised 4.8% higher, and such positive revision trends are often correlated with stock price appreciation, suggesting potential future gains.
- Market Position: GRDN currently holds a Zacks Rank of #1 (Strong Buy), further reflecting market recognition of its position and growth potential within the medical drugs industry.
See More
Akebia (AKBA) Q4 2025 Earnings Call Transcript
See More
Akebia Expects Significant Revenue Growth for Vafseo in 2026
- Revenue Growth Outlook: Akebia anticipates significant revenue growth for Vafseo by 2026, driven by expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates, enhancing the company's competitive position in the chronic kidney disease treatment market.
- Clinical Trial Advancements: The company plans to initiate mid-stage trials for AKB-097 targeting rare kidney diseases in the second half of 2026, with initial data expected in 2027, which will provide new growth avenues for its product pipeline.
- Strong Financial Position: As of Q4, Akebia reported cash and cash equivalents of approximately $184.8 million, which is expected to fund its current operating plan for at least two years, providing financial stability for research and market expansion.
- Positive Market Sentiment: On Stocktwits, retail sentiment around AKBA stock shifted from 'neutral' to 'bullish', reflecting investor optimism regarding the accelerating adoption of Vafseo and the company's cash reserves, despite a 28% decline in stock price over the past year.
See More
Akebia Therapeutics Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Akebia reported total net product revenue of $227 million for 2025, with Vafseo and Auryxia as key contributors, indicating strong performance in the kidney disease treatment market and positioning Vafseo as a potential standard of care in a $1 billion market opportunity.
- Clinical Data Support: At the ASN meeting, Akebia presented clinical data showing Vafseo's hospitalization rate was 7.7% lower than the ESA comparator, with a 16% reduction in hospitalization days, which is expected to enhance physician utilization and drive sales growth.
- Pipeline Expansion: The company plans to initiate a Phase II open-label trial for AKB-097 in the second half of 2026, indicating Akebia's strategic expansion into rare kidney diseases, leveraging its expertise in kidney drug development to enhance market competitiveness.
- Improved Financial Position: Total revenues for Q4 2025 were $57.6 million, with net loss reduced to $12.2 million compared to $22.8 million in the same quarter last year, reflecting effective cost control and revenue enhancement measures, while cash and cash equivalents stood at $184.8 million, sufficient to support operations for the next two years.
See More
Akebia Reports Q4 Earnings Beat with Revenue Growth
- Earnings Performance: Akebia's Q4 GAAP EPS of -$0.05 missed expectations by $0.01, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported Q4 revenue of $57.6 million, a 23.9% year-over-year increase, surpassing market expectations by $11.51 million, suggesting sustained demand for its products and laying a foundation for future performance.
- Market Reaction: Although the EPS fell short of expectations, the strong revenue growth may boost investor confidence and drive stock price recovery, reflecting a positive sentiment towards Akebia's future prospects.
- Industry Outlook: Akebia presented its future outlook at the Guggenheim Securities Biotech Summit, highlighting upcoming catalysts that could attract more investor interest in its long-term potential.
See More
